Anti-CGRP/anti-IL-23 bispecific antibodies and uses thereof

IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention...

Full description

Saved in:
Bibliographic Details
Main Authors Wu, Xiufeng, Benschop, Robert Jan, Demarest, Stephen John
Format Patent
LanguageEnglish
Published 03.03.2020
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

Abstract IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.
AbstractList IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.
Author Demarest, Stephen John
Benschop, Robert Jan
Wu, Xiufeng
Author_xml – fullname: Wu, Xiufeng
– fullname: Benschop, Robert Jan
– fullname: Demarest, Stephen John
BookMark eNrjYmDJy89L5WSwdswrydR1dg8K0E8EsTx9dI2MFZIyiwtSkzPTMpMVQKJJ-SmZqcVAZopCaTGQUZKRWpSan8bDwJqWmFOcyguluRkU3VxDnD10Uwvy41OLCxKTU_NSS-JDgw0NTM3NTQxNnYyMiVEDAPNpL9c
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID US10577415B2
GroupedDBID EVB
ID FETCH-epo_espacenet_US10577415B23
IEDL.DBID EVB
IngestDate Fri Jul 19 13:02:15 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US10577415B23
Notes Application Number: US201815963167
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200303&DB=EPODOC&CC=US&NR=10577415B2
ParticipantIDs epo_espacenet_US10577415B2
PublicationCentury 2000
PublicationDate 20200303
PublicationDateYYYYMMDD 2020-03-03
PublicationDate_xml – month: 03
  year: 2020
  text: 20200303
  day: 03
PublicationDecade 2020
PublicationYear 2020
RelatedCompanies Eli Lilly and Company
RelatedCompanies_xml – name: Eli Lilly and Company
Score 3.2607174
Snippet IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title Anti-CGRP/anti-IL-23 bispecific antibodies and uses thereof
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200303&DB=EPODOC&locale=&CC=US&NR=10577415B2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-LmBxWkb2Hr0nUVKWK_nOK2sq2yt9G0KdSHdtgO_31zoXO-6NtxgXAJXO6S_O53AHdmypD7dkj6psmJrqU6YXFkkIRpPIlFyswkxcZ4YoxC_XU5WDbgY1sLI3lCvyQ5ovCoWPh7Jc_r9e4Ry5XYyrLLMqEqHv2F5ar17RiRVj2qurblBVN36qiOY4VzdTKzsJ0tBk9bHNd7mEYjz773bmNVyvp3SPGPYT8Qs-XVCTR43oJDZ9t5rQUH4_rDW4i175Wn8PCUVxlxnmdBN0Lp5Y30qcIyrJVEvI-CWlYgKlCIibIphYDpHS_SM7j1vYUzIsKK1c-SV-F8ZzA9h2Ze5PwCFJNr2jBJBjFnhrjZRPcGp3qPyv7Bmsl5Gzp_z9P5b_ASjnD7JLqKXkGz-tzwaxFuK3Yj9-kb-viC2w
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTkXnVwXpW9i6dm1Firh0tdPug33I3sbSplAf2mE7_PfNhc75om_HBcIlcLlL8rvfAdzbMUPuW4u0bZsTQ4sNwsKVSSKm8SgUKTOTFBuDoenPjddFZ1GBj20tjOQJ_ZLkiMKjQuHvhTyv17tHLFdiK_MmS4Qqe_JmjquWt2NEWrV01e06vfHIHVGVUmc-VYcTB9vZYvDsiuN6z0J2Xkyd3rtYlbL-HVK8I9gfi9nS4hgqPK1DjW47r9XhYFB-eAux9L38BB6f0yIh9GUybq5Q6gekrSsswVpJxPsoqGUZogKFGCmbXAiY3vEsPoU7rzejPhFWLH-WvJxPdwbrZ1BNs5Sfg2JzTbOiqBNyZoqbzerB5LrR0mX_YM3m_AIaf8_T-G_wFmr-bBAsg_7w7RIOcSsl0kq_gmrxueHXIvQW7Ebu2TdCeoXI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Anti-CGRP%2Fanti-IL-23+bispecific+antibodies+and+uses+thereof&rft.inventor=Wu%2C+Xiufeng&rft.inventor=Benschop%2C+Robert+Jan&rft.inventor=Demarest%2C+Stephen+John&rft.date=2020-03-03&rft.externalDBID=B2&rft.externalDocID=US10577415B2